Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.6K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.6K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.1K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.1K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.0K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.0K
Depressants01:28

Depressants

593
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
593
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

865
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
865

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serotonergic Polypharmacology of 2-Halogenated Tryptamines.

bioRxiv : the preprint server for biology·2026
Same author

Can Psychiatric Genetics Advance Without Incorporating a Life Course Perspective?

Biological psychiatry·2026
Same author

An Open-Source Restraint System for Magnetic Resonance Imaging in Awake Rats.

eNeuro·2026
Same author

Investigating the polygenic relationship between heavy cannabis use and schizophrenia in the All of Us Research Program.

Psychological medicine·2025
Same author

FARESHARE: An open-source apparatus for assessing drinking microstructure in socially housed rats.

NPP - digital psychiatry and neuroscience·2025
Same author

Effects of prenatal cannabis exposure on offspring mental health: A focus on the role of the immune system.

Neuroscience and biobehavioral reviews·2025

Related Experiment Video

Updated: Apr 4, 2026

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
08:05

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

10.3K

Desipramine enhances the ability of paliperidone to decrease alcohol drinking.

David T Chau1, Jibran Y Khokhar1, Danielle Gulick1

  • 1Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.

Journal of Psychiatric Research
|September 8, 2015
PubMed
Summary
This summary is machine-generated.

A combination of desipramine and paliperidone significantly reduced alcohol drinking in animal models. This synergistic effect suggests a potential new treatment for alcohol use disorder in schizophrenia patients.

Keywords:
AlcoholismDual disorderHamsterRatSchizophreniaTreatment

More Related Videos

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.7K
Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
09:26

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication

Published on: February 6, 2019

22.4K

Related Experiment Videos

Last Updated: Apr 4, 2026

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
08:05

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

10.3K
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

1.7K
Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication
09:26

Disruption of Frontal Lobe Neural Synchrony During Cognitive Control by Alcohol Intoxication

Published on: February 6, 2019

22.4K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Addiction Medicine

Background:

  • Alcohol use disorder (AUD) frequently co-occurs with schizophrenia, worsening patient outcomes.
  • Clozapine, an atypical antipsychotic, reduces drinking in these patients but has significant toxicity.
  • Developing safer alternatives with similar pharmacologic actions is crucial.

Purpose of the Study:

  • To evaluate paliperidone's efficacy in attenuating alcohol consumption.
  • To assess if desipramine potentiates paliperidone's effect on alcohol drinking.
  • To explore a novel therapeutic strategy for AUD in schizophrenia.

Main Methods:

  • Utilized alcohol-preferring P rats and Syrian golden hamsters as animal models.
  • Administered daily subcutaneous injections of paliperidone and/or desipramine over 20 days.
  • Assessed the initiation and acquisition of alcohol consumption and preference.

Main Results:

  • Paliperidone alone showed slight, transient attenuation of alcohol initiation.
  • Desipramine alone did not affect alcohol drinking.
  • The combination of desipramine and paliperidone synergistically prevented alcohol drinking initiation and acquisition in rats and suppressed intake in hamsters.

Conclusions:

  • The combination of desipramine and paliperidone demonstrates a synergistic effect in reducing alcohol consumption.
  • This drug combination represents a promising new therapeutic approach for treating alcohol use disorder in patients with schizophrenia.